The current status of biomarkers for predicting toxicity

Bibliography

• Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32(1):56-67
   PubMed Web of Science ®Google Scholar
• Sistare FD, DeGeorge JJ. Preclinical predictors of clinical safety: opportunities for improvement. Clin Pharmacol Ther 2007;82(2):210-14
   PubMed Web of Science ®Google Scholar
• Shanks N, Greek R, Greek J. Are animal models predictive for humans? Philos Ethics Humanit Med 2009;4:2
   PubMedGoogle Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
   PubMed Web of Science ®Google Scholar
• Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
   PubMed Web of Science ®Google Scholar
• NCI dictionary of terms. Available from: http://www.cancer.gov/dictionary?cdrid=45618
   Google Scholar
• Taube SE. Biomarkers in oncology. Ann NY Acad Sci 2009;1180:111-18
   PubMed Web of Science ®Google Scholar
• Amur S, Frueh FW, Lesko LJ, Huang SM. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomarkers Med 2008;2(3):305-11
   PubMed Web of Science ®Google Scholar
• Jones R. Biomarkers: casting the net wide. Nature 2010;466(7310):S11-12
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol 2013;25(3):305-12
   PubMed Web of Science ®Google Scholar
• George S, Reichardt P, Lechner T, et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2012;23(12):3180-7
   PubMed Web of Science ®Google Scholar
• Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5(9):1023-38
   PubMed Web of Science ®Google Scholar
• O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008;245(3):206-18
   PubMed Web of Science ®Google Scholar
• Piccini JP, Whellan DJ, Berridge BR, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 2009;158(3):317-26
   PubMed Web of Science ®Google Scholar
• Tarrant JM. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci 2010;117(1):4-16
   PubMed Web of Science ®Google Scholar
• Mikaelian I, Scicchitano M, Mendes O, et al. Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs. Toxicol Pathol 2013;41(1):18-31
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
   PubMed Web of Science ®Google Scholar
• Mendrick DL. Genomic and genetic biomarkers of toxicity. Toxicology 2008;245(3):175-81
   PubMed Web of Science ®Google Scholar
• Fielden MR, Brennan R, Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 2007;99(1):90-100
   PubMed Web of Science ®Google Scholar
• Goodsaid FM. Identification and measurement of genomic biomarkers of nephrotoxicity. J Pharmacol Toxicol Methods 2004;49(3):183-6
   PubMedGoogle Scholar
• Davis JW II, Goodsaid FM, Bral CM, et al. Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol Appl Pharmacol 2004;200(1):16-26
   PubMed Web of Science ®Google Scholar
• Collings FB, Vaidya VS. Novel technologies for the discovery and quantitation of biomarkers of toxicity. Toxicology 2008;245(3):167-74
   PubMed Web of Science ®Google Scholar
• Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 2010;245(1):134-42
   PubMed Web of Science ®Google Scholar
• Goodsaid F. Are we ready for novel preclinical safety biomarkers? Preclinica 2004;2(4):1-3
   Google Scholar
• Jurewicz J, Hanke W, Radwan M, Bonde JP. Environmental factors and semen quality. Int J Occup Med Environ Health 2009;22(4):305-29
   PubMed Web of Science ®Google Scholar
• Boekelheide K. Commentary on “incidence and nature of testicular toxicity findings ...”. Birth Defects Res B Dev Reprod Toxicol 2011;92(6):501-3
   PubMed Web of Science ®Google Scholar
• Whorton D, Krauss RM, Marshall S, Milby TH. Infertility in male pesticide workers. Lancet 1977;2(8051):1259-61
   PubMed Web of Science ®Google Scholar
• Whorton D, Milby TH, Krauss RM, Stubbs HA. Testicular function in DBCP exposed pesticide workers. J Occup Med 1979;21(3):161-6
   PubMedGoogle Scholar
• Eaton M, Schenker M, Whorton MD, et al. Seven-year follow-up of workers exposed to 1,2-dibromo-3-chloropropane. J Occup Med 1986;28(11):1145-50
   PubMedGoogle Scholar
• Bonde JP, Giwercman A, Ernst E. Identifying environmental risk to male reproductive function by occupational sperm studies: logistics and design options. Occup Environ Med 1996;53(8):511-19
   PubMed Web of Science ®Google Scholar
• Klinefelter GR. Saga of a sperm fertility biomarker. Anim Reprod Sci 2008;105(1-2):90-103
   PubMed Web of Science ®Google Scholar
• Ostermeier GC, Dix DJ, Miller D, et al. Spermatozoal RNA profiles of normal fertile men. Lancet 2002;360(9335):772-7
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou Z, Xu M, et al. A spermatogenesis-related gene expression profile in human spermatozoa and its potential clinical applications. J Mol Med (Berl) 2004;82(5):317-24
   PubMed Web of Science ®Google Scholar
• Aoki VW, Liu L, Carrell DT. A novel mechanism of protamine expression deregulation highlighted by abnormal protamine transcript retention in infertile human males with sperm protamine deficiency. Mol Hum Reprod 2006;12(1):41-50
   PubMed Web of Science ®Google Scholar
• Steger K, Wilhelm J, Konrad L, et al. Both protamine-1 to protamine-2 mRNA ratio and Bcl2 mRNA content in testicular spermatids and ejaculated spermatozoa discriminate between fertile and infertile men. Hum Reprod 2008;23(1):11-16
   PubMed Web of Science ®Google Scholar
• Miller D, Ostermeier GC. Towards a better understanding of RNA carriage by ejaculate spermatozoa. Hum Reprod Update 2006;12(6):757-67
   PubMed Web of Science ®Google Scholar
• Trasler JM. Gamete imprinting: setting epigenetic patterns for the next generation. Reprod Fertil Dev 2006;18(1-2):63-9
   PubMed Web of Science ®Google Scholar
• Hammoud SS, Purwar J, Pflueger C, et al. Alterations in sperm DNA methylation patterns at imprinted loci in two classes of infertility. Fertil Steril 2010;94(5):1728-33
   PubMed Web of Science ®Google Scholar
• Houshdaran S, Cortessis VK, Siegmund K, et al. Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm. PLoS One 2007;2(12):e1289
   PubMed Web of Science ®Google Scholar
• Marques CJ, Carvalho F, Sousa M, Barros A. Genomic imprinting in disruptive spermatogenesis. Lancet 2004;363(9422):1700-2
   PubMed Web of Science ®Google Scholar
• Marques CJ, Costa P, Vaz B, et al. Abnormal methylation of imprinted genes in human sperm is associated with oligozoospermia. Mol Hum Reprod 2008;14(2):67-74
   PubMed Web of Science ®Google Scholar
• Poplinski A, Tuttelmann F, Kanber D, et al. Idiopathic male infertility is strongly associated with aberrant methylation of MEST and IGF2/H19 ICR1. Int J Androl 2010;33(4):642-9
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sato A, Otsu E, et al. Aberrant DNA methylation of imprinted loci in sperm from oligospermic patients. Hum Mol Genet 2007;16(21):2542-51
   PubMed Web of Science ®Google Scholar
• Pathak S, Kedia-Mokashi N, Saxena M, et al. Effect of tamoxifen treatment on global and insulin-like growth factor 2-H19 locus-specific DNA methylation in rat spermatozoa and its association with embryo loss. Fertil Steril 2009;91(5 Suppl):2253-63
   PubMed Web of Science ®Google Scholar
• Sato A, Hiura H, Okae H, et al. Assessing loss of imprint methylation in sperm from subfertile men using novel methylation polymerase chain reaction Luminex analysis. Fertil Steril 2011;95(1):129-34; 34 e1-4
   PubMed Web of Science ®Google Scholar
• Boissonnas CC, Abdalaoui HE, Haelewyn V, et al. Specific epigenetic alterations of IGF2-H19 locus in spermatozoa from infertile men. Eur J Hum Genet 2010;18(1):73-80
   PubMed Web of Science ®Google Scholar
• Wu W, Shen O, Qin Y, et al. Idiopathic male infertility is strongly associated with aberrant promoter methylation of methylenetetrahydrofolate reductase (MTHFR). PLoS ONE 2010;5(11):e13884
   PubMedGoogle Scholar
• Navarro-Costa P, Nogueira P, Carvalho M, et al. Incorrect DNA methylation of the DAZL promoter CpG island associates with defective human sperm. Hum Reprod 2010;25(10):2647-54
   PubMed Web of Science ®Google Scholar
• Aston KI, Punj V, Liu L, Carrell DT. Genome-wide sperm deoxyribonucleic acid methylation is altered in some men with abnormal chromatin packaging or poor in vitro fertilization embryogenesis. Fertil Steril 2012;97(2):285-92
   PubMed Web of Science ®Google Scholar
• Chan D, Delbes G, Landry M, et al. Epigenetic alterations in sperm DNA associated with testicular cancer treatment. Toxicol Sci 2012;125(2):532-43
   PubMed Web of Science ®Google Scholar
• Pacheco SE, Anderson LM, Sandrof MA, et al. Sperm mRNA transcripts are indicators of sub-chronic low dose testicular injury in the Fischer 344 rat. PLoS One 2012;7(8):e44280
   PubMedGoogle Scholar
• Pacheco SE, Houseman EA, Christensen BC, et al. Integrative DNA methylation and gene expression analyses identify DNA packaging and epigenetic regulatory genes associated with low motility sperm. PLoS One 2011;6(6):e20280
   PubMedGoogle Scholar
• Carrell DT. Epigenetics of the male gamete. Fertil Steril 2012;97(2):267-74
   PubMed Web of Science ®Google Scholar
• Jenkins TG, Carrell DT. The paternal epigenome and embryogenesis: poising mechanisms for development. Asian J Androl 2011;13(1):76-80
   PubMed Web of Science ®Google Scholar
• Hsu RK, McCulloch CE, Dudley RA, et al. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 2013;24(1):37-42
   PubMed Web of Science ®Google Scholar
• Bucaloiu ID, Kirchner HL, Norfolk ER, et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012;81(5):477-85
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008;48:463-93
   PubMed Web of Science ®Google Scholar
• Hodgson S, Nieuwenhuijsen MJ, Hansell A, et al. Excess risk of kidney disease in a population living near industrial plants. Occup Environ Med 2004;61(8):717-19
   PubMed Web of Science ®Google Scholar
• Van Vleet TR, Schnellmann RG. Toxic nephropathy: environmental chemicals. Semin Nephrol 2003;23(5):500-8
   PubMed Web of Science ®Google Scholar
• Wu X, Liang Y, Jin T, et al. Renal effects evolution in a Chinese population after reduction of cadmium exposure in rice. Environ Res 2008;108(2):233-8
   PubMed Web of Science ®Google Scholar
• Nordberg GF, Jin T, Wu X, et al. Prevalence of kidney dysfunction in humans - relationship to cadmium dose, metallothionein, immunological and metabolic factors. Biochimie 2009;91(10):1282-5
   PubMed Web of Science ®Google Scholar
• Gonick HC. Nephrotoxicity of cadmium & lead. Indian J Med Res 2008;128(4):335-52
   PubMed Web of Science ®Google Scholar
• Roels HA, Hoet P, Lison D. Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity. Ren Fail 1999;21(3-4):251-62
   PubMed Web of Science ®Google Scholar
• Roels H, Lauwerys R, Konings J, et al. Renal function and hyperfiltration capacity in lead smelter workers with high bone lead. Occup Environ Med 1994;51(8):505-12
   PubMed Web of Science ®Google Scholar
• de Burbure C, Buchet JP, Leroyer A, et al. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 2006;114(4):584-90
   PubMed Web of Science ®Google Scholar
• Jarup L. Hazards of heavy metal contamination. Br Med Bull 2003;68:167-82
   PubMed Web of Science ®Google Scholar
• Hassan AM, Sheashaa HA, Fattah MF, et al. Study of ochratoxin A as an environmental risk that causes renal injury in breast-fed Egyptian infants. Pediatr Nephrol 2006;21(1):102-5
   PubMed Web of Science ®Google Scholar
• Petrik J, Zanic-Grubisic T, Barisic K, et al. Apoptosis and oxidative stress induced by ochratoxin A in rat kidney. Arch Toxicol 2003;77(12):685-93
   PubMed Web of Science ®Google Scholar
• Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008;73(5):595-607
   PubMed Web of Science ®Google Scholar
• Isnard Bagnis C, Deray G, Baumelou A, et al. Herbs and the kidney. Am J Kidney Dis 2004;44(1):1-11
   Google Scholar
• Grollman AP, Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia. J Am Soc Nephrol 2007;18(11):2817-23
   PubMed Web of Science ®Google Scholar
• Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007;104(29):12129-34
   PubMed Web of Science ®Google Scholar
• Soderland P, Lovekar S, Weiner DE, et al. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis 2010;17(3):254-64
   PubMed Web of Science ®Google Scholar
• Bacchetta J, Dubourg L, Juillard L, Cochat P. Non-drug-induced nephrotoxicity. Pediatr Nephrol (Berlin, Germany) 2009;24(12):2291-300
   PubMed Web of Science ®Google Scholar
• Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334(22):1448-60
   PubMed Web of Science ®Google Scholar
• Anders MW. Metabolism of drugs by the kidney. Kidney Int 1980;18(5):636-47
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011;121(11):4210-21
   PubMed Web of Science ®Google Scholar
• Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273(7):4135-42
   PubMed Web of Science ®Google Scholar
• Ichimura T, Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118(5):1657-68
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006;290(2):F517-29
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010;28(5):478-85
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008;1(3):200-8
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ford GM, Waikar SS, et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009;76(1):108-14
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Yang L. Kidney injury molecule-1. Curr Opin Crit Care 2010;16(6):556-61
   PubMed Web of Science ®Google Scholar
• Peralta CA, Katz R, Bonventre JV, et al. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012;60(6):904-11
   PubMed Web of Science ®Google Scholar
• Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012;34(1):43-62
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy A, Ajay AK, Hoffmann D, et al. Fibrinogen {beta}-derived B{beta}15-42 peptide protects against kidney ischemia/reperfusion injury. Blood 2011;118(7):1934-42
   PubMed Web of Science ®Google Scholar
• Ajay AK, Saikumar J, Bijol V, Vaidya VS. Heterozygosity for fibrinogen results in efficient resolution of kidney ischemia reperfusion injury. PLoS One 2012;7(9):e45628
   PubMedGoogle Scholar
• Hoffmann D, Bijol V, Krishnamoorthy A, et al. Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury. Am J Pathol 2012;181(3):818-28
   PubMed Web of Science ®Google Scholar
• Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007;204(3):571-82
   PubMed Web of Science ®Google Scholar
• Petzelbauer P, Zacharowski PA, Miyazaki Y, et al. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005;11(3):298-304
   PubMed Web of Science ®Google Scholar
• Sorensen I, Rong S, Susnik N, et al. Bbeta(15-42) attenuates the effect of ischemia-reperfusion injury in renal transplantation. J Am Soc Nephrol 2011;22(10):1887-96
   PubMed Web of Science ®Google Scholar
• Cruz-Topete D, Iwaki T, Ploplis VA, Castellino FJ. Delayed inflammatory responses to endotoxin in fibrinogen-deficient mice. J Pathol 2006;210(3):325-33
   PubMed Web of Science ®Google Scholar
• Drew AF, Tucker HL, Liu H, et al. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 2001;281(6):F1157-63
   PubMed Web of Science ®Google Scholar
• Akassoglou K, Adams RA, Bauer J, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA 2004;101(17):6698-703
   PubMed Web of Science ®Google Scholar
• Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995;9(16):2020-33
   PubMed Web of Science ®Google Scholar
• Saikumar J, Hoffmann D, Kim TM, et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129(2):256-67
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141(5):672-5
   PubMed Web of Science ®Google Scholar
• Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011;57(1):84-91
   PubMed Web of Science ®Google Scholar
• Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010;119(2):87-95
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106(11):4402-7
   PubMed Web of Science ®Google Scholar
• Burt D, Crowell SJ, Ackley DC, et al. Application of emerging biomarkers of acute kidney injury in development of kidney-sparing polypeptide-based antibiotics. Drug Chem Toxicol; In press.
   Google Scholar
• Schomaker S, Warner R, Bock J, et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci 2013;132(2):276-83
   PubMed Web of Science ®Google Scholar
• Goodsaid FM, Frueh FW, Mattes W. The predictive safety testing consortium: a synthesis of the goals, challenges and accomplishments of the critical path. Drug Discov Today Technol 2007;4(2):47-50
   PubMedGoogle Scholar
• Goodsaid FM, Blank M, Dieterle F, et al. Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther 2009;86(5):490-6
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28(5):436-40
   PubMed Web of Science ®Google Scholar
• Lock EA. Sensitive and early markers of renal injury: where are we and what is the way forward? Toxicol Sci 2010;116(1):1-4
   PubMed Web of Science ®Google Scholar
• Sistare FD, Dieterle F, Troth S, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 2010;28(5):446-54
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Bonventre JV. Biomarkers: in medicine, drug discovery, and environmental health. John Wiley & SOns, Inc; Hoboken, NJ: 2010
   Google Scholar
• Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245(3):194-205
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry. Drug-Induced Liver Injury: premarketing Clinical Evaluation. 2007. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM174090.pdf
   Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89(6):806-15
   PubMed Web of Science ®Google Scholar
• Dieterle F. The European IMI SAFE-T consortium: qualification of translation safety biomarkers. Toxicol Lett 2009;189:S157
   Web of Science ®Google Scholar
• FDA. Guidance for Industry. Pharmacogenomic Data Submissions. 2005. Available from: www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf
   Google Scholar
• FDA. Critical Path Opportunities List. 2006. Available from: www.fda.gov/downloads/scienceresearch/specialtopics/CriticalPathinitiative/CriticalPathOpportunitiesreports/UCM077258.pdf
   Google Scholar
• Altar CA, Amakye D, Bounos D, et al. A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin Pharmacol Ther 2008;83(2):368-71
   PubMed Web of Science ®Google Scholar
• Institute of Medicine of the National Academy of Sciences. Consensus Report. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease; 2010
   Google Scholar
• Goodsaid FM, Freuh F. Regulatory guidance and validation of toxicologic biomarkers. In: DeCaprio AP, editor. Toxicologic biomarkers. Taylor & Francis Group; New York: 2006. p. 187-220
   Google Scholar
• Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006;7(5):773-82
   PubMed Web of Science ®Google Scholar
• Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 2008;245(3):219-23
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry. Qualification Process for Drug Development Tools. 2010. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM230597.pdf
   Google Scholar
• FDA. Biomarker Qualification Program. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualification Program/ucm284076.htm
   Google Scholar